ClinicalTrials.gg
CompletedNCT01838681Updated Aug 9, 2017Results posted

Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

A Phase 3 interventional study of Placebo and Brexpiprazole in Major Depressive Disorder, sponsored by H. Lundbeck A/S. Completed at 107 sites in 16 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-08-09.

Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,986
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.

Enrollment
2nd of 24
1,986 · median 189
Started
2013
with 6 others
Phase 3
16 of 24
none open now
Registered
9th of 24
by date
Lead sponsor
4 of 24
H. Lundbeck A/S

Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 2nd largest by enrollment, is one of 7 that started in 2013, is one of 16 in phase 3, and was the 9th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing brexpiprazole in Depressive Disorder, Major, or all of them as a file.
02

Study summary

To evaluate the long-term efficacy and safety of brexpiprazole as an adjunctive treatment to an antidepressant treatment (ADT) for adult patients with Major Depressive Disorder (MDD).

Read the detailed description

The total duration of the study was 32 weeks and the study consisted of Periods A, B, and A+. Patients entered the study in Period A and were treated open-label with one of six commercially available antidepressant treatments (ADTs) for 8 weeks. Patients who met the blinded response criteria at the Week 6 Visit, were deemed early responders and were withdrawn from the study. At Week 8, patients with inadequate response to placebo + ADT, as per the randomisation criteria, entered Period B and were randomised to received double-blind brexpiprazole + ADT or placebo + ADT for 24 weeks. Non-randomised patients continued in Period A+ and received placebo + ADT until the end of the study. The primary objective was to compare the efficacy and safety of brexpiprazole with placebo. This comparison occurred Period B; therefore, the focus is Period B.

03

Conditions studied

  • Major Depressive Disorder
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient is an outpatient consulting a psychiatrist.
  • The patient has an MDD diagnosed according to ™. The current Major Depressive Episode (MDE) should be confirmed using the Mini International Neuropsychiatric Interview (MINI).
  • The patient has a moderate to severe depression and an insufficient response to at least one and no more than three adequate antidepressant treatments.
  • The patient agrees to protocol-defined use of effective .

Exclusion criteria

Exclusion Criteria:

  • The patient has any current psychiatric disorder or Axis I disorder (™ criteria), established as the primary diagnosis, other than MDD.
  • The patient has a current Axis II (DSM-IV-TR™) diagnosis of borderline, antisocial, paranoid, schizoid, schizotypical or histrionic personality disorder.
  • The patient has experienced/experiences hallucinations, delusions or any psychotic symptomatology in the current MDE.
  • The patient suffers from mental retardation, organic mental disorders, or mental disorders due to a general medical condition (DSM-IV-TR™ criteria).
  • The patient, in the opinion of the investigator or according to Columbia-Suicide Severity Rating Scale (C-SSRS), is at significant risk of suicide.
  • The patient has had neuroleptic malignant syndrome.
  • The patient has any relevant medical history or current presence of systemic disease.
  • The patient has, at the Screening Visit an abnormal that is, in the investigator's opinion, .
  • The patient has a history of cancer, other than basal cell or Stage 1 squamous cell carcinoma of the skin, that has not been in remission for >5 years prior to the first dose of IMP.
  • The patient is, in the investigator's opinion, unlikely to comply with the protocol or is unsuitable for any reason.

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,986 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo adjunct to open-label treatment with a commercially available antidepressant (ADT)

    Drug: Placebo · Drug: ADT

  • Experimental
    Brexpiprazole

    Brexpiprazole adjunct to open-label treatment with a commercially available ADT

    Drug: Brexpiprazole · Drug: ADT

Interventions

  • DrugPlacebo

    Once daily, tablets, orally

  • 1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 1 mg/day

  • DrugADT

    Duloxetine, escitalopram, fluoxetine, paroxetine IR, sertraline, venlafaxine XR; dosing according to label

06

What researchers measure

Primary outcomes

  1. Full Remission During the Randomised Treatment Period

    Full remission is defined as a Montomery and Åsberg Depression Rating Scale (MADRS) total score ≤10 and a ≥50% decrease from randomisation in MADRS total score for at least 8 consecutive weeks during randomized treatment. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). The MADRS total score is the sum of the 10 items.

    Time frame: From randomisation to end of Period B (24 weeks)

Secondary outcomes

  1. Full Functional Remission During the Randomised Treatment Period

    Full functional remission is defined as a Sheehan Disability Scale (SDS) total score \<=6 and all SDS domain scores \<=2 observed for at least 8 consecutive weeks during the randomised treatment period. The SDS assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.

    Time frame: From randomisation to end of Period B (24 weeks)

  2. Full Global Score Remission During the Randomised Treatment Period

    Full global score remission is defined as a Clinical Global Impression - Severity of Illness (CGI-S) score \<=2 observed for at least 8 consecutive weeks during the randomised treatment period. The CGI-S is a 7-point scale where the clinician rates the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis, on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.

    Time frame: From randomisation to end of Period B (24 weeks)

  3. Total Time in Remission During the Randomised Treatment Period

    The total time the patient spends in remission during randomised treatment. Remission is defined as a MADRS total score \<=10 and a \>=50% decrease from randomisation in MADRS total score. Time in remission is defined as the sum of days over all periods between Period B visits where remission was obtained. The period between two visits is counted as in remission if the patient was in remission when the period started.

    Time frame: From randomisation to end of Period B (24 weeks)

  4. Time to Full Remission During the Randomised Treatment Period

    The time from randomisation until full remission has been obtained. Full remission is defined as a MADRS total score ≤10 and a ≥50% decrease from randomisation in MADRS total score for at least 8 consecutive weeks during randomised treatment. The time to full remission was calculated using Kaplan-Meier Methods.

    Time frame: From randomisation to end of Period B (24 weeks)

  5. Full Remission Sustained During the Randomised Treatment Period

    Full remission sustained is defined as having obtained full remission and remain in remission until completion of the study. Full remission is defined as a MADRS total score ≤10 and a ≥50% decrease from randomisation in MADRS total score for at least 8 consecutive weeks during randomised treatment.

    Time frame: From randomisation to end of Period B (24 weeks)

  6. Change From Randomisation to Week 6 in MADRS Total Score During the Randomised Treatment Period

    The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). The MADRS total score is the sum of the 10 items.

    Time frame: From randomisation to week 6

  7. Change From Randomisation to Week 24 in MADRS Total Score During the Randomised Treatment Period

    The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). The MADRS total score is the sum of the 10 items.

    Time frame: From randomisation to end of Period B (24 weeks)

  8. Response at Week 6 During the Randomised Treatment Period

    Response is defined as a \>=50% decrease from randomisation in MADRS total score.

    Time frame: From randomisation to week 6

  9. Response at Week 24 During the Randomised Treatment Period

    Response is defined as a \>=50% decrease from randomisation in MADRS total score.

    Time frame: From randomisation to end of Period B (24 weeks)

  10. Remission at Week 6 During the Randomised Treatment Period

    Remission is defined as a MADRS total score \<=10 and a \>=50% decrease from randomisation in MADRS total score.

    Time frame: From randomisation to week 6

  11. Remission at Week 24 in the Randomised Treatment Period

    Remission is defined as a MADRS total score \<=10 and a \>=50% decrease from randomisation in MADRS total score.

    Time frame: From randomisation to end of Period B (24 weeks)

  12. Change From Randomisation to Week 6 in SDS Total Score During the Randomised Treatment Period

    The SDS assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.

    Time frame: From randomisation to week 6

  13. Change From Randomisation to Week 24 in SDS Total Score During the Randomised Treatment Period

    The SDS assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.

    Time frame: From randomisation to end of Period B (24 weeks)

  14. Change From Randomisation to Week 6 in CGI-S Score During the Randomised Treatment Period

    The CGI-S is a 7-point scale where the clinician rates the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.

    Time frame: From randomisation to week 6

  15. Change From Randomisation to Week 24 in CGI-S Score During the Randomised Treatment Period

    The CGI-S is a 7-point scale where the clinician rates the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.

    Time frame: From randomisation to end of Period B (24 weeks)

  16. Change From Randomisation to Week 6 in Q-LES-Q (SF) Total Score During the Randomised Treatment Period

    The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. The Q-LES-Q short form (SF) contains 16 items from the general activities section. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good). The total score is the sum of the first 14 items. The last two scores are stand-alone items. The total score ranges from 14 to 70.

    Time frame: From randomisation to week 6

  17. Change From Randomisation to Week 24 in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q (SF)) Total Score During the Randomised Treatment Period

    The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. The Q-LES-Q short form (SF) contains 16 items from the general activities section. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good). The total score is the sum of the first 14 items. The last two scores are stand-alone items. The total score ranges from 14 to 70.

    Time frame: From randomisation to end of Period B (24 weeks)

07

Results

Posted Aug 9, 2017

Participant flow

1986 patients were enrolled; 1982 received open-label ADT plus double-blind placebo in the 8-week Period A. In the 24-week Period B, 886 patients were randomised and 885 were treated with open-label ADT plus double-blind brexpiprazole or placebo. Non-randomised patients continued in Period A+ and received open-label ADT plus double-blind placebo.

Period A
Participant flow — Period A
MilestonePeriod A Placebo and ADT (8 Weeks)Period B Placebo and ADT (24 Weeks Randomised Treatment)Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment)Period A+ Placebo and ADT (Non-randomised Patients)
Started1986000
Completed1661000
Not completed325000
Withdrew: Adverse event39000
Withdrew: Lack of efficacy21000
Withdrew: Early response148000
Withdrew: Withdrawal by subject70000
Withdrew: Protocol violation16000
Withdrew: Non-compliance with imp6000
Withdrew: Lost to follow-up4000
Withdrew: Withdrawal before treatment4000
Withdrew: Administrative or other reasons17000
Period B/A+
Participant flow — Period B/A+
MilestonePeriod A Placebo and ADT (8 Weeks)Period B Placebo and ADT (24 Weeks Randomised Treatment)Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment)Period A+ Placebo and ADT (Non-randomised Patients)
Started0442444770
Completed0380349653
Not completed06295117
Withdrew: Adverse event0132716
Withdrew: Lack of efficacy09116
Withdrew: Withdrawal by subject0283547
Withdrew: Protocol violation0146
Withdrew: Non-compliance with imp0233
Withdrew: Lost to follow-up02511
Withdrew: Withdrawal before treatment0100
Withdrew: Administrative or other reasons061028

Outcome measures

PrimaryFull Remission During the Randomised Treatment Period

Full remission is defined as a Montomery and Åsberg Depression Rating Scale (MADRS) total score ≤10 and a ≥50% decrease from randomisation in MADRS total score for at least 8 consecutive weeks during randomized treatment. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). The MADRS total score is the sum of the 10 items.

Time frame:
From randomisation to end of Period B (24 weeks)
Reported as:
Number · participants
Full Remission During the Randomised Treatment Period
participantsPeriod B Placebo and ADT (24 Weeks Randomised Treatment)Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment)
Full Remission During the Randomised Treatment Period11095
Statistical analysis
  • Period B Placebo and ADT (24 Weeks Randomised Treatment) vs Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment) · Regression, Logistic · p = 0.2641 · Odds ratio (or): 0.83 · 95% CI 0.60 to 1.15Model included MADRS total score at the randomisation visit, treatment group, country, and the randomisation criteria used
SecondaryFull Functional Remission During the Randomised Treatment Period

Full functional remission is defined as a Sheehan Disability Scale (SDS) total score \<=6 and all SDS domain scores \<=2 observed for at least 8 consecutive weeks during the randomised treatment period. The SDS assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.

Time frame:
From randomisation to end of Period B (24 weeks)
Reported as:
Number · participants
Full Functional Remission During the Randomised Treatment Period
participantsPeriod B Placebo and ADT (24 Weeks Randomised Treatment)Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment)
Full Functional Remission During the Randomised Treatment Period7368
SecondaryFull Global Score Remission During the Randomised Treatment Period

Full global score remission is defined as a Clinical Global Impression - Severity of Illness (CGI-S) score \<=2 observed for at least 8 consecutive weeks during the randomised treatment period. The CGI-S is a 7-point scale where the clinician rates the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis, on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.

Time frame:
From randomisation to end of Period B (24 weeks)
Reported as:
Number · participants
Full Global Score Remission During the Randomised Treatment Period
participantsPeriod B Placebo and ADT (24 Weeks Randomised Treatment)Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment)
Full Global Score Remission During the Randomised Treatment Period143121
SecondaryTotal Time in Remission During the Randomised Treatment Period

The total time the patient spends in remission during randomised treatment. Remission is defined as a MADRS total score \<=10 and a \>=50% decrease from randomisation in MADRS total score. Time in remission is defined as the sum of days over all periods between Period B visits where remission was obtained. The period between two visits is counted as in remission if the patient was in remission when the period started.

Time frame:
From randomisation to end of Period B (24 weeks)
Reported as:
Mean · Number of days
Total Time in Remission During the Randomised Treatment Period
Number of daysPeriod B Placebo and ADT (24 Weeks Randomised Treatment)Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment)
Total Time in Remission During the Randomised Treatment Period33.5 ± 46.130.0 ± 44.3
SecondaryTime to Full Remission During the Randomised Treatment Period

The time from randomisation until full remission has been obtained. Full remission is defined as a MADRS total score ≤10 and a ≥50% decrease from randomisation in MADRS total score for at least 8 consecutive weeks during randomised treatment. The time to full remission was calculated using Kaplan-Meier Methods.

Time frame:
From randomisation to end of Period B (24 weeks)
Reported as:
Median · Days
Time to Full Remission During the Randomised Treatment Period
DaysPeriod B Placebo and ADT (24 Weeks Randomised Treatment)Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment)
Time to Full Remission During the Randomised Treatment PeriodNA (NA to NA)NA (NA to NA)
SecondaryFull Remission Sustained During the Randomised Treatment Period

Full remission sustained is defined as having obtained full remission and remain in remission until completion of the study. Full remission is defined as a MADRS total score ≤10 and a ≥50% decrease from randomisation in MADRS total score for at least 8 consecutive weeks during randomised treatment.

Time frame:
From randomisation to end of Period B (24 weeks)
Reported as:
Number · participants
Full Remission Sustained During the Randomised Treatment Period
participantsPeriod B Placebo and ADT (24 Weeks Randomised Treatment)Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment)
Full Remission Sustained During the Randomised Treatment Period10584
SecondaryChange From Randomisation to Week 6 in MADRS Total Score During the Randomised Treatment Period

The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). The MADRS total score is the sum of the 10 items.

Time frame:
From randomisation to week 6
Reported as:
Least squares mean · units on a scale
Change From Randomisation to Week 6 in MADRS Total Score During the Randomised Treatment Period
units on a scalePeriod B Placebo and ADT (24 Weeks Randomised Treatment)Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment)
Change From Randomisation to Week 6 in MADRS Total Score During the Randomised Treatment Period-5.9 ± 0.4-6.3 ± 0.4
SecondaryChange From Randomisation to Week 24 in MADRS Total Score During the Randomised Treatment Period

The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). The MADRS total score is the sum of the 10 items.

Time frame:
From randomisation to end of Period B (24 weeks)
Reported as:
Least squares mean · Units on a scale
Change From Randomisation to Week 24 in MADRS Total Score During the Randomised Treatment Period
Units on a scalePeriod B Placebo and ADT (24 Weeks Randomised Treatment)Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment)
Change From Randomisation to Week 24 in MADRS Total Score During the Randomised Treatment Period-12.6 ± 0.6-11.5 ± 0.6
SecondaryResponse at Week 6 During the Randomised Treatment Period

Response is defined as a \>=50% decrease from randomisation in MADRS total score.

Time frame:
From randomisation to week 6
Reported as:
Number · participants
Response at Week 6 During the Randomised Treatment Period
participantsPeriod B Placebo and ADT (24 Weeks Randomised Treatment)Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment)
Response at Week 6 During the Randomised Treatment Period7682
SecondaryResponse at Week 24 During the Randomised Treatment Period

Response is defined as a \>=50% decrease from randomisation in MADRS total score.

Time frame:
From randomisation to end of Period B (24 weeks)
Reported as:
Number · participants
Response at Week 24 During the Randomised Treatment Period
participantsPeriod B Placebo and ADT (24 Weeks Randomised Treatment)Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment)
Response at Week 24 During the Randomised Treatment Period236223
SecondaryRemission at Week 6 During the Randomised Treatment Period

Remission is defined as a MADRS total score \<=10 and a \>=50% decrease from randomisation in MADRS total score.

Time frame:
From randomisation to week 6
Reported as:
Number · participants
Remission at Week 6 During the Randomised Treatment Period
participantsPeriod B Placebo and ADT (24 Weeks Randomised Treatment)Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment)
Remission at Week 6 During the Randomised Treatment Period4653
SecondaryRemission at Week 24 in the Randomised Treatment Period

Remission is defined as a MADRS total score \<=10 and a \>=50% decrease from randomisation in MADRS total score.

Time frame:
From randomisation to end of Period B (24 weeks)
Reported as:
Number · participants
Remission at Week 24 in the Randomised Treatment Period
participantsPeriod B Placebo and ADT (24 Weeks Randomised Treatment)Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment)
Remission at Week 24 in the Randomised Treatment Period198176
SecondaryChange From Randomisation to Week 6 in SDS Total Score During the Randomised Treatment Period

The SDS assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.

Time frame:
From randomisation to week 6
Reported as:
Least squares mean · units on a scale
Change From Randomisation to Week 6 in SDS Total Score During the Randomised Treatment Period
units on a scalePeriod B Placebo and ADT (24 Weeks Randomised Treatment)Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment)
Change From Randomisation to Week 6 in SDS Total Score During the Randomised Treatment Period-3.0 ± 0.3-2.9 ± 0.3
SecondaryChange From Randomisation to Week 24 in SDS Total Score During the Randomised Treatment Period

The SDS assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment.

Time frame:
From randomisation to end of Period B (24 weeks)
Reported as:
Least squares mean · units on a scale
Change From Randomisation to Week 24 in SDS Total Score During the Randomised Treatment Period
units on a scalePeriod B Placebo and ADT (24 Weeks Randomised Treatment)Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment)
Change From Randomisation to Week 24 in SDS Total Score During the Randomised Treatment Period-6.7 ± 0.5-5.5 ± 0.5
SecondaryChange From Randomisation to Week 6 in CGI-S Score During the Randomised Treatment Period

The CGI-S is a 7-point scale where the clinician rates the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.

Time frame:
From randomisation to week 6
Reported as:
Least squares mean · units on a scale
Change From Randomisation to Week 6 in CGI-S Score During the Randomised Treatment Period
units on a scalePeriod B Placebo and ADT (24 Weeks Randomised Treatment)Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment)
Change From Randomisation to Week 6 in CGI-S Score During the Randomised Treatment Period-0.8 ± 0.1-0.8 ± 0.1
SecondaryChange From Randomisation to Week 24 in CGI-S Score During the Randomised Treatment Period

The CGI-S is a 7-point scale where the clinician rates the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill.

Time frame:
From randomisation to end of Period B (24 weeks)
Reported as:
Least squares mean · units on a scale
Change From Randomisation to Week 24 in CGI-S Score During the Randomised Treatment Period
units on a scalePeriod B Placebo and ADT (24 Weeks Randomised Treatment)Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment)
Change From Randomisation to Week 24 in CGI-S Score During the Randomised Treatment Period-1.7 ± 0.1-1.5 ± 0.1
SecondaryChange From Randomisation to Week 6 in Q-LES-Q (SF) Total Score During the Randomised Treatment Period

The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. The Q-LES-Q short form (SF) contains 16 items from the general activities section. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good). The total score is the sum of the first 14 items. The last two scores are stand-alone items. The total score ranges from 14 to 70.

Time frame:
From randomisation to week 6
Reported as:
Least squares mean · units on a scale
Change From Randomisation to Week 6 in Q-LES-Q (SF) Total Score During the Randomised Treatment Period
units on a scalePeriod B Placebo and ADT (24 Weeks Randomised Treatment)Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment)
Change From Randomisation to Week 6 in Q-LES-Q (SF) Total Score During the Randomised Treatment Period3.5 ± 0.43.2 ± 0.4
SecondaryChange From Randomisation to Week 24 in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q (SF)) Total Score During the Randomised Treatment Period

The original Q-LES-Q is a patient self-rated scale designed to measure the degree of enjoyment and satisfaction experienced by patients in various areas of daily life. It consists of 93 items to measure: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. The Q-LES-Q short form (SF) contains 16 items from the general activities section. Each item is rated on a 5-point scale ranging from 1 (very poor) to 5 (very good). The total score is the sum of the first 14 items. The last two scores are stand-alone items. The total score ranges from 14 to 70.

Time frame:
From randomisation to end of Period B (24 weeks)
Reported as:
Least squares mean · units on a scale
Change From Randomisation to Week 24 in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q (SF)) Total Score During the Randomised Treatment Period
units on a scalePeriod B Placebo and ADT (24 Weeks Randomised Treatment)Period B Brexpiprazole and ADT (24 Weeks Randomised Treatment)
Change From Randomisation to Week 24 in Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q (SF)) Total Score During the Randomised Treatment Period7.7 ± 0.76.2 ± 0.7

Adverse events

Collected over Randomisation to end of study (28 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo and ADT—13/441 (2.9%)97/441 (22%)
Brexpiprazole and ADT—9/444 (2%)108/444 (24.3%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventPlacebo and ADTBrexpiprazole and ADT
Suicidal ideationPsychiatric disorders3/4412/444
Intentional overdoseInjury, poisoning and procedural complications2/4410/444
Ovarian cystReproductive system and breast disorders1/3020/307
InfluenzaInfections and infestations1/4410/444
Forearm fractureInjury, poisoning and procedural complications1/4410/444
False positive investigation resultInvestigations1/4410/444
Ruptured cerebral aneurysmNervous system disorders1/4410/444
SciaticaNervous system disorders1/4410/444
Major depressionPsychiatric disorders1/4411/444
Self injurious behaviourPsychiatric disorders1/4410/444
Most frequent other events
Most frequent other events
EventPlacebo and ADTBrexpiprazole and ADT
Weight increasedInvestigations22/44142/444
NasopharyngitisInfections and infestations34/44128/444
HeadacheNervous system disorders31/44134/444
Accidental overdoseInjury, poisoning and procedural complications25/44127/444

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Enrolled Patients
Mean47.3 ± 12.0
Sex: Female, Male
Sex: Female, Male(Participants)All Enrolled Patients
Female1402
Male584
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Enrolled Patients
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American19
White1918
More than one race0
Unknown or Not Reported46
Region of Enrollment
Region of Enrollment(participants)All Enrolled Patients
Russian Federation121
Romania15
United States78
Ukraine189
United Kingdom168
Canada30
Latvia84
Sweden85
Finland136
Poland325
Mexico72
Bulgaria119
Lithuania76
Germany325
Estonia161
Korea, Republic of2
08

Study locations

107 sites
  • US041
    Little Rock, Arkansas, United States
  • US043
    Cerritos, California, United States
  • US042
    Temecula, California, United States
  • US053
    Flowood, Mississippi, United States
  • US040
    Brooklyn, New York, United States
  • US046
    Houston, Texas, United States
  • US052
    Houston, Texas, United States
  • US047
    Milwaukee, Wisconsin, United States
  • BG007
    Kardjali, Bulgaria
  • BG002
    Pazardzhik, Bulgaria
  • BG003
    Ruse, Bulgaria
  • BG001
    Sofia, Bulgaria
  • BG004
    Sofia, Bulgaria
  • BG005
    Varna, Bulgaria
  • BG006
    Varna, Bulgaria
  • CA003
    Burlington, Canada
  • CA004
    Edmonton, Alberta, Canada
  • CA001
    Kingston, Canada
  • CA002
    Montral, Canada
  • CA005
    Montreal, Canada
  • EE002
    Tallinn, Estonia
  • EE003
    Tallinn, Estonia
  • EE006
    Tallinn, Estonia
  • EE001
    Tartu, Estonia
  • EE005
    Tartu, Estonia
  • EE004
    Voru, Estonia
  • FI002
    Helsinki, Finland
  • FI003
    Helsinki, Finland
  • FI006
    Helsinki, Finland
  • FI001
    Kuopio, Finland
  • FI007
    Pori, Finland
  • FI009
    Tampere, Finland
  • DE007
    Berlin, Germany
  • DE014
    Berlin, Germany
  • DE015
    Berlin, Germany
  • DE006
    Bielefeld, Germany
  • DE010
    Bochum, Germany
  • DE012
    Gelsenkirchen, Germany
  • DE009
    Hannover, Germany
  • DE022
    Hattingen, Germany
  • DE008
    Heidelberg, Germany
  • DE017
    Leipzig, Germany
  • DE001
    Nuernberg, Germany
  • DE004
    Nuernberg, Germany
  • DE002
    Schwerin, Germany
  • DE016
    Wiesbaden, Germany
  • KR001
    Seoul, Korea, Republic of
  • KR004
    Seoul, Korea, Republic of
  • LV004
    Daugavpils, Latvia
  • LV005
    Jelgava, Latvia
  • LV002
    Liepaja, Latvia
  • LV003
    Riga, Latvia
  • LV001
    Strenci, Latvia
  • LT006
    Kaunas Region, Lithuania
  • LT003
    Kaunas, Lithuania
  • LT001
    Palanga, Lithuania
  • LT005
    Silute, Lithuania
  • LT002
    Vilnius, Lithuania
  • LT004
    Vilnius, Lithuania
  • MX009
    Guadalajara, Mexico
  • MX008
    Leon, Mexico
  • MX003
    Monterrey, Nuevo Len, Mexico
  • MX002
    Monterrey, Mexico
  • PL010
    Bialystok, Poland
  • PL016
    Bialystok, Poland
  • PL017
    Bydgoszcz, Poland
  • PL007
    Chelmno, Poland
  • PL002
    Gdansk, Poland
  • PL011
    Gorlice, Poland
  • PL018
    Kielce, Poland
  • PL013
    Leszno, Poland
  • PL001
    Lublin, Poland
  • PL006
    Lublin, Poland
  • PL014
    Szczecin, Poland
  • PL012
    Torun, Poland
  • PL019
    Torun, Poland
  • RO003
    Bucuresti, Romania
  • RO006
    Bucuresti, Romania
  • RO001
    Iasi, Romania
  • RO004
    Timisoara, Romania
  • RU002
    Moscow, Russian Federation
  • RU004
    Moscow, Russian Federation
  • RU003
    Saint-Petersburg, Russian Federation
  • RU006
    Saint-Petersburg, Russian Federation
  • RU007
    Saint-Petersburg, Russian Federation
  • RU010
    Saint-Petersburg, Russian Federation
  • RU014
    Saint-Petersburg, Russian Federation
  • RU012
    Saratov, Russian Federation
  • RU005
    Stavropol, Russian Federation
  • SE008
    Halmstad, Sweden
  • SE006
    Malmo, Sweden
  • SE009
    Skovde, Sweden
  • SE001
    Stockholm, Sweden
  • UA006
    Kharkiv, Ukraine
  • UA007
    Kherson,Vil. Stepanivka, Ukraine
  • UA003
    Kiev, Ukraine
  • UA014
    Kiev, Ukraine
  • UA002
    Kyiv, Ukraine
  • UA005
    Lviv, Ukraine
  • UA012
    Ternopil, Ukraine

Showing the first 100 of 107 sites across 16 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2013, a primary completion of Jun 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2017, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2013
First posted
Apr 24, 2013
Start
Jun 2013
Primary completionActual
Jun 2016
CompletionActual
Jun 2016
Results first posted
Aug 9, 2017
Last update
Aug 9, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 9, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01838681
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Apr 24, 2013
Start date
Jun 2013
Primary completion
Jun 2016
Completion
Jun 2016
Results posted
Aug 9, 2017
Last update
Aug 9, 2017

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@lundbeck.com

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion